Abstract
Abstract
Purpose
The aim of this study was to propose the qualitative and quantitative approaches to evaluate the skeletal muscle ultrasound images of 23 Pompe disease (i.e., acid maltase deficiency, AMD) patients and 14 normal subjects.
Methods
A cohort of 23 AMD patients and 14 normal subjects has been investigated. We compared the B-mode echo intensity of the rectus femoris muscle with that of its surrounding fat (subcutaneous fat) and proposed a qualitative grading method. Quantitative analysis of the region of interest (ROI) with the echo intensity and the segmented area was also performed.
Results
Qualitative results showed that AMD patients without clinical symptoms (without undergoing ERT) had the highest distribution of Grade 1, and AMD patients undergoing ERT had the widest distribution of Grade 2, and control group (n = 14) with the highest distribution of Grade 1. Using the segmented area approach, quantitative results showed that AMD patients undergoing ERT had the largest and widest distribution. Meanwhile the control subjects (normal subjects) had the lowest and the narrowest areas. The echo intensity of the segmented ROI of AMD patients undergoing ERT displayed the highest and widest (inhomogeneous) distributions. By contrast, the echo intensity of AMD patients without clinical symptoms was slightly increased and with low inhomogeneity.
Conclusion
The proposed ultrasonography-based qualitative and quantitative approach may be used to evaluate the severity of muscle destruction for AMD patients. Besides, the quantitative segmented area with regression analysis could help predict the incidence of onset of Pompe disease patients.
Funder
Ministry of Science and Technology, Taiwan
Publisher
Springer Science and Business Media LLC
Subject
Biomedical Engineering,General Medicine
Reference43 articles.
1. van der Ploeg, A. T., & Reuser, A. J. J. (2008). Pompe’s disease. The Lancet,372(9646), 1342–1353.
2. Lim, J. A., Li, L., & Raben, N. (2014). Pompe’s disease from pathophysiology to therapy and back again. Frontiers in Aging Neuroscience,6(177), 1–14.
3. Toscano, A., & Schoser, B. (2013). Enzyme replacement therapy in late-onset Pompe disease: A systematic literature review. Journal of Neurology,260(4), 951–959.
4. Kishnani, P. S., Corzo, D., Leslie, N. D., et al. (2009). Early treatment with algulcosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatric Research,66(3), 329–335.
5. Rohrbach, M., Klein, A., Köhli-Wiesner, A., et al. (2010). CRIM-negative infantile Pompe disease: 42-month treatment outcome. Journal of Inherited Metabolic Disease,33(6), 751–757.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献